Release Date: December 10, 2025
Expiration Date: December 10, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in breast cancer. In this educational program, these experts discuss the evolving treatment landscape across breast cancer subtypes and lines of care. Gamified case-based discussion will focus on integrating the latest practice-changing data into clinical practice to optimize care for patients with breast cancer.
This educational activity is an archive of the live symposium held on November 13, 2025.
Target Audience
This educational activity is directed toward physicians, advanced practice professionals, nurses, pharmacists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent evidence from pivotal clinical trials assessing novel agents and expanded indications for existing therapies in patients with breast cancer
- Incorporate potentially practice-changing data into individualized treatment plans for patients with breast cancer
Tiffany A. Traina, MD, FASCO
Associate Attending Physician
Vice Chair, Oncology; Department of Medicine
Section Head, Triple-Negative Breast Cancer Clinical Research
Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Cornell Medicine
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Aktis Oncology, AstraZeneca, BioNTech SE, Daiichi Sankyo, Ellipses Pharma, Exact Sciences, Genentech/Roche, Gilead Sciences, Merck, Pfizer, Stemline Therapeutics, TerSera, Veracyte; Grant/Research Funding (to institution): AstraZeneca, Astellas Pharma, BioNTech SE, Daiichi Sankyo, Genentech/Roche, Pfizer
Nour Abuhadra, MD
Assistant Professor
Director, Rare Breast Cancer Program, Department of Medicine
Co-Section Head, Triple-Negative Breast Cancer Clinical Research
Program Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Nour Abuhadra, MD, has no relevant financial relationships with ineligible companies.
Joshua Z. Drago, MD, MS
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AmMax Bio, AstraZeneca, Genagon Therapeutics, MEDACorp, NuProbe, Revelio Therapeutics; Grant/Research Funding (to institution): AstraZeneca, Jazz Pharmaceuticals, Merck & Co, Orum Therapeutics
Ruth O’Regan, MD
Chair, Department of Medicine
Charles A. Dewey Professor of Medicine & Oncology
University of Rochester Medical Center School of Medicine and
Dentistry
Associate Director, Education and Mentoring
Wilmot Cancer Institute
Rochester, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Biotheranostics, Gilead, Lilly, Puma, Regor Pharmaceuticals; Grant/Research Funding: Novartis, Puma
Vered Stearns, MD, FASCO
Professor of Medicine
Director for Translational Breast Cancer Research
Interim Chief, Breast Medical Oncology Hematology and Medical
Oncology
Associate Director for Clinical Research, Sandra and Edward Meyer
Cancer Center
Weill Cornell Medicine
New York, NY
Disclosures: Chair, DSMB: AstraZeneca
Neil Vasan, MD, PhD
Assistant Professor
Director, Breast Cancer Translational Research
Department of Medicine, NYU Grossman School of Medicine
Perlmutter Cancer Center, NYU Langone Health
New York, NY
Disclosures: Advisor, Consultant Speaker Honoraria Recipient: Apertor Pharmaceuticals, Avenzo Therapeutics, Reactive Biosciences, Scorpion Therapeutics; Grant/Research Funding: Gilead; Executive Role: Meliora Therapeutics (member of SAB); Royalty of Patent Benefits: Wolters Kluwer; Ownership Interests in Privately Held Companies: Heligenics, Meliora Therapeutics, Reactive Biosciences
Anna Weiss, MD
Associate Professor
Department of Surgery, Oncology
University of Rochester Medical Center
Rochester, NY
Disclosure: Anna Weiss, MD, has no relevant financial relationships with ineligible companies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.